Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026)
Scholar Rock Holding's (SRRK) quarterly Amortization of Deferred Charges came in at $1.5 million in Q1 2026, up 24.09% year-on-year from $1.2 million in Q1 2025, and up 11.19% quarter-over-quarter from $1.4 million in Q4 2025.
Scholar Rock Holding (SRRK) Amortization of Deferred Charges (2019 - 2026) Analysis & Trends
Scholar Rock Holding's Amortization of Deferred Charges history runs 8 years deep, the most recent figure standing at $1.5 million for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges rose 24.09% year-over-year to $1.5 million in Q1 2026; TTM through Mar 2026 was $5.6 million, a 12.95% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, up 0.73% from the prior year.
- Amortization of Deferred Charges advanced to $1.5 million in Q1 2026 per SRRK's latest filing, from $1.4 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $6.9 million in Q4 2023 and bottomed at -$3.4 million in Q3 2023.
- The 5-year median for Amortization of Deferred Charges is $1.3 million (2025), against an average of $1.2 million.
- Across the five-year window, Amortization of Deferred Charges surged 4601.36% in 2023 and sank 96.86% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at $147000.0 in 2022, then jumped by 4601.36% to $6.9 million in 2023, then slipped by 27.39% to $5.0 million in 2024, then plunged by 72.4% to $1.4 million in 2025, then grew by 11.19% to $1.5 million in 2026.
- Per Business Quant, the three latest SRRK Amortization of Deferred Charges figures stand at $1.5 million (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,094.26 Bn | 68,093.97 Bn | - |
| 2 | Nanobiotix | 1,939.09 Bn | 1,939.02 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.53 Bn | 468.74 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.34 Bn | 116.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.13 Bn | 61.38 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.96 Bn | 62.96 Bn | - |
| 8 | Argenx Se | 56.38 Bn | 51.20 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn |
| 10 | Scholar Rock Holding | 6.28 Bn | 6.28 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Sep 30, 2025 | 1.34 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Jun 30, 2025 | 1.29 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 71,000.00 |
| Sep 30, 2024 | 71,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Mar 31, 2024 | 77,000.00 |
| Dec 31, 2023 | 6.91 Mn |
| Dec 31, 2023 | 6.91 Mn |